LOGO
LOGO

Canadian News

Allarity's DRP Companion Diagnostic For Dovitinib Earns Peer-Reviewed Spotlight, Stock Jumps

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News
rttnewslogo20mar2024

Allarity Therapeutics Inc.'s (ALLR) data from clinical validation of DRP companion diagnostic for Dovitinib has been published in the peer-reviewed journal PLOS ONE. The news sent the stock soaring during after-hours trading.

According to the published data, the DRP-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to unselected patients.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update - April 27 – May 01, 2026

May 01, 2026 15:54 ET
Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.

Latest Updates on COVID-19